(S (NP (DT The) (JJ current) (NN pandemic)) (VP (VBZ has) (VP (VBN highlighted) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NNS methodologies)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (ADVP (ADVP (RB quickly)) (CC and) (ADVP (RB reliably))) (VP (VB prioritize) (NP (ADJP (RB clinically) (VBN approved)) (NNS compounds)) (PP (IN for) (NP (NP (PRP$ their) (JJ potential) (NN effectiveness)) (PP (IN for) (NP (NP (NNP SARS) (HYPH -) (NNP CoV)) (HYPH -) (NP (CD 2) (NNS infections))))))))))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ past) (NN decade))) (, ,) (NP (NN network) (NN medicine)) (VP (VBZ has) (VP (VBN developed) (CC and) (VBN validated) (NP (NP (JJ multiple) (JJ predictive) (NNS algorithms)) (PP (IN for) (NP (NN drug) (NN repurposing)))) (, ,) (S (VP (VBG exploiting) (NP (NP (DT the) (JJ sub-cellular) (ADJP (NN network) (HYPH -) (VBN based)) (NN relationship)) (PP (IN between) (NP (NP (DT a) (NN drug) (POS 's)) (NNS targets) (CC and) (NN disease) (NNS genes)))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD deployed) (NP (NP (NNS algorithms)) (VP (VBG relying) (PP (IN on) (NP (NP (NP (JJ artificial) (NN intelligence)) (, ,) (NP (NN network) (NN diffusion)) (, ,) (CC and) (NP (NN network) (NN proximity))) (, ,) (NP (NP (NN tasking)) (NP (DT each))) (PP (IN of) (NP (PRP them))))) (S (VP (TO to) (VP (VB rank) (NP (CD 6,340) (NNS drugs)) (PP (IN for) (NP (NP (PRP$ their) (VBN expected) (NN efficacy)) (PP (IN against) (NP (NNP SARS) (HYPH -) (NNP CoV) (HYPH -) (NNP 2))))))))))) (. .))
(S (S (VP (TO To) (VP (VB test) (NP (DT the) (NNS predictions))))) (, ,) (NP (PRP we)) (VP (VBD used) (PP (IN as) (NP (NN ground) (NN truth))) (NP (NP (NP (CD 918) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBD had) (VP (VBN been) (ADVP (RB experimentally)) (VP (VBN screened) (PP (IN in) (NP (NN VeroE6) (NNS cells))))))))) (, ,) (CC and) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN under) (NP (NP (JJ clinical) (NN trial)) (, ,) (NP (NP (DT that) (NN capture)) (NP (NP (NP (DT the) (JJ medical) (NN community) (POS 's)) (NN assessment)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN with) (NP (JJ potential) (NML (NN COVID) (HYPH -) (CD 19)) (NN efficacy)))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP find) (SBAR (IN that) (S (SBAR (IN while) (S (NP (JJS most) (NNS algorithms)) (VP (VBP offer) (NP (JJ predictive) (NN power)) (PP (IN for) (NP (DT these) (NN ground) (NN truth) (NNS data)))))) (, ,) (NP (DT no) (JJ single) (NN method)) (VP (VBZ offers) (NP (ADJP (RB consistently) (JJ reliable)) (NNS outcomes)) (PP (IN across) (NP (DT all) (NNS datasets) (CC and) (NNS metrics))))))) (. .))
(S (NP (DT This)) (VP (VBD prompted) (NP (PRP us)) (S (VP (TO to) (VP (VB develop) (NP (NP (DT a) (JJ multimodal) (NN approach)) (SBAR (WHNP (WDT that)) (S (VP (VBZ fuses) (NP (NP (DT the) (NNS predictions)) (PP (IN of) (NP (DT all) (NNS algorithms)))) (, ,) (S (VP (VBG showing) (SBAR (IN that) (S (NP (NP (DT a) (NN consensus)) (PP (IN among) (NP (DT the) (JJ different) (JJ predictive) (NNS methods)))) (ADVP (RB consistently)) (VP (VBZ exceeds) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (DT the) (JJS best) (JJ individual) (NNS pipelines))))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP (NP (CD 76)) (PP (IN of) (NP (NP (DT the) (CD 77) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB successfully)) (VP (VBD reduced) (NP (JJ viral) (NN infection)))))))) (VP (VBP do) (RB not) (VP (VB bind) (NP (NP (DT the) (NN proteins)) (VP (VBN targeted) (PP (IN by) (NP (NP (NNP SARS) (HYPH -) (NNP CoV) (HYPH -) (CD 2)) (, ,) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT these) (NNS drugs)) (VP (VBP rely) (PP (IN on) (NP (NP (ADJP (NN network) (HYPH -) (VBN based)) (NNS actions)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (RB not) (VP (VB be) (VP (VBN identified) (S (VP (VBG using) (NP (ADJP (NP (NN docking)) (HYPH -) (VBN based)) (NNS strategies)))))))))))))))))))))))) (. .))
(S (NP (DT These) (NNS advances)) (VP (VP (VBP offer) (NP (DT a) (JJ methodological) (NN pathway)) (S (VP (TO to) (VP (VB identify) (NP (NP (NP (JJ repurposable) (NNS drugs)) (PP (IN for) (NP (JJ future) (NNS pathogens)))) (CC and) (NP (NP (VBN neglected) (NNS diseases)) (VP (VBN underserved) (PP (IN by) (NP (DT the) (NNS costs)))))))))) (CC and) (VP (VBD extended) (NP (NP (NN timeline)) (PP (IN of) (NP (ADJP (FW de) (FW novo)) (NN drug) (NN development)))))) (. .))
